Luyan PharmaLtd Inkomsten in het verleden
Verleden criteriumcontroles 3/6
Luyan PharmaLtd has been growing earnings at an average annual rate of 8.7%, while the Healthcare industry saw earnings growing at 2% annually. Revenues have been growing at an average rate of 7.6% per year. Luyan PharmaLtd's return on equity is 11.7%, and it has net margins of 1.8%.
Belangrijke informatie
8.7%
Groei van de winst
5.5%
Groei van de winst per aandeel
| Healthcare Groei van de industrie | 7.0% |
| Inkomstengroei | 7.6% |
| Rendement op eigen vermogen | 11.7% |
| Nettomarge | 1.8% |
| Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe Luyan PharmaLtd geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 20,484 | 359 | 790 | 6 |
| 30 Jun 24 | 20,127 | 365 | 778 | 6 |
| 31 Mar 24 | 20,140 | 367 | 776 | 6 |
| 31 Dec 23 | 19,846 | 364 | 764 | 6 |
| 30 Sep 23 | 19,914 | 356 | 780 | 4 |
| 30 Jun 23 | 20,146 | 365 | 777 | 5 |
| 31 Mar 23 | 19,667 | 353 | 777 | 4 |
| 01 Jan 23 | 19,463 | 345 | 764 | 4 |
| 30 Sep 22 | 18,866 | 325 | 750 | 4 |
| 30 Jun 22 | 18,412 | 322 | 753 | 3 |
| 31 Mar 22 | 18,017 | 313 | 729 | 3 |
| 31 Dec 21 | 17,545 | 306 | 725 | 3 |
| 30 Sep 21 | 17,135 | 286 | 703 | 3 |
| 30 Jun 21 | 16,795 | 290 | 676 | 4 |
| 31 Mar 21 | 16,340 | 280 | 667 | 4 |
| 31 Dec 20 | 15,535 | 267 | 636 | 4 |
| 30 Sep 20 | 15,284 | 272 | 629 | 5 |
| 30 Jun 20 | 15,051 | 265 | 631 | 5 |
| 31 Mar 20 | 14,942 | 263 | 617 | 5 |
| 31 Dec 19 | 15,009 | 256 | 614 | 5 |
| 30 Sep 19 | 14,224 | 240 | 581 | 4 |
| 30 Jun 19 | 13,360 | 220 | 525 | 3 |
| 31 Mar 19 | 12,328 | 192 | 515 | 3 |
| 31 Dec 18 | 11,501 | 180 | 479 | 2 |
| 30 Sep 18 | 10,755 | 171 | 458 | 2 |
| 30 Jun 18 | 10,000 | 149 | 430 | 2 |
| 31 Mar 18 | 9,317 | 140 | 383 | 1 |
| 31 Dec 17 | 8,338 | 131 | 351 | 1 |
| 30 Sep 17 | 7,705 | 132 | 311 | 1 |
| 30 Jun 17 | 7,227 | 125 | 302 | 0 |
| 31 Mar 17 | 7,001 | 117 | 290 | 0 |
| 31 Dec 16 | 6,983 | 116 | 283 | 0 |
| 30 Sep 16 | 6,995 | 116 | 276 | 0 |
| 30 Jun 16 | 6,875 | 114 | 276 | 0 |
| 31 Mar 16 | 6,741 | 114 | 265 | 0 |
| 31 Dec 15 | 6,626 | 113 | 264 | 0 |
| 31 Dec 14 | 6,300 | 109 | 283 | 0 |
| 31 Dec 13 | 5,520 | 108 | 242 | 0 |
Kwaliteitswinsten: 002788 has high quality earnings.
Groeiende winstmarge: 002788's current net profit margins (1.8%) are lower than last year (1.8%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 002788's earnings have grown by 8.7% per year over the past 5 years.
Versnelling van de groei: 002788's earnings growth over the past year (0.7%) is below its 5-year average (8.7% per year).
Winst versus industrie: 002788 earnings growth over the past year (0.7%) exceeded the Healthcare industry -5.7%.
Rendement op eigen vermogen
Hoge ROE: 002788's Return on Equity (11.7%) is considered low.